IP Library › Granted Patent US 12674167
Granted Patent B2
US 12674167 · App. 17/593,951 · Granted Jul 7, 2026

Aptamer specifically binding to cancer stem cells, and use thereof

Inventors: Jae Ho Kim (Busan, KR); Dae Kyoung Kim (Yangsan-si, KR)
C12N15/1138A23L33/13A23L33/40A61K9/0019A61K9/1611A61K9/1623A61K9/2013A61K9/2018A61K9/2059A61K9/4825A61K9/4858A61K9/4866A61K31/7088A61P35/00G01N33/5759A23V2002/00C12N2310/16G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12674167
App. No.
17/593,951
Granted
Jul 7, 2026
Kind
B2
Abstract

The present invention relates to aptamers that specifically bind to cancer stem cells. The aptamers according to the present invention specifically bind to cancer stem cells and reduce cell adhesion ability, cell proliferation, drug resistance and cell migration, which are characteristics of cancer stem cells, thus having excellent anticancer effects. Therefore, the aptamer may be used in various ways in the fields of cancer diagnosis, prognosis prediction, and treatment.

Claims (23)

1 . An aptamer that specifically binds to cancer stem cells, comprising a nucleic acid sequence represented by SEQ ID NO: 4 or SEQ ID NO: 5.

2 . The aptamer that specifically binds to cancer stem cells according to claim 1 , wherein the aptamer specifically binds to human CD166.

3 . The aptamer that specifically binds to cancer stem cells according to claim 1 , wherein the aptamer has a size of 70 to 80 mer.

4 . The aptamer that specifically binds to cancer stem cells according to claim 1 , wherein the cancer stem cells are at least one selected from the group consisting of breast cancer stem cells, lung cancer stem cells, ovarian cancer stem cells, and colon cancer stem cells.

5 . A composition for diagnosing cancer, comprising the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

6 . A kit for diagnosing cancer, comprising the composition for diagnosing cancer according to claim 5 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

7 . The kit for diagnosing cancer according to claim 6 , wherein the kit for diagnosing cancer is a PCR kit, a DNA chip kit, a protein chip kit, or a microarray kit.

8 . A method for diagnosing cancer, comprising:

reacting a biological sample with the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

9 . A pharmaceutical composition comprising the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

10 . An anticancer adjuvant composition comprising the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

11 . A food composition comprising the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

12 . A composition for cancer-specific drug delivery, comprising the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.

13 . A method for treating cancer, comprising:

administering to a subject the aptamer that specifically binds to cancer stem cells according to claim 1 ,

wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, ovarian cancer and colon cancer.